Novavax stock discussion and Tuesday’s trading at $21.34 as of 11:10 AM EDT.
Novavax (NASDAQ:NVAX) said its COVID-19 vaccine is now available in the UK in 1 million doses. In February, the UK’s health regulator approved Nuvaxovid for adults and in August for teens.
The WHO reports 23.6 million coronavirus cases and 190,000 deaths in the UK. 151.2 million vaccine doses have been given as of Aug. 31. COVID-19 vaccines currently available in the UK are Moderna’s (MRNA), AstraZeneca’s (AZN), and Pfizer/(BNTX) BioNTech’s shots.
Moderna Has A Bright Future, So Purchase It Immediately
“With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die, it’s more important than ever to consider any vaccine offered by the National Health Service,” NVAX CEO Stanley Erck said in a statement.
The Novavax vaccine uses more conventional technology than the mRNA-based ones developed by Pfizer (PFE), BioNTech (BNTX), and Moderna (mRNA). Premarket shares were up 4.4% but have fallen 87% year to date, while the S&P 500 has fallen 23%.
NVAX stock discussion: performance
Novavax stock is at a two-year low as its Covid vaccine, Nuvaxovid is used more in the United States. Novavax stock discussion (NASDAQ:NVAX) has fallen 86% in 2022 and 90% in the past 12 months. The company cut its full-year revenue guidance in August and posted a disappointing second quarter amid poor demand for its Covid-19 vaccine. NVAX stock gained 5.3% to $19.86 premarket.
Novavax (NVAX) asked the FDA to approve Nuvaxovid for emergency use in July. Since then, the CDC says 6,278 people have received two doses. Novavax has been given 772,900 doses in the U.S.
Featured Image – Megapixl © Filmfoto
Author Jowi Kwasu 
